RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast Cancer.
Siang-Boon KohKenneth RossSteven Jay IsakoffNsan MelkonjanLei HeKarina J MatissekAndrew SchultzErica L MayerTiffany A TrainaLisa Anne CareyHope S RugoMinetta C LiuVered StearnsAdam LangenbucherSrinivas Vinod SaladiSridhar RamaswamyMichael S LawrenceLeif W EllisenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
These findings identify RASAL2 as a mediator of TNBC chemoresistance that rewires MAPK feedback and cross-talk to confer profound collateral sensitivity to combination MEK1/2 and EGFR inhibitors.